NovaDigm is developing innovative vaccines to protect patients from fungal and bacterial infections. Our lead product candidates target the fungal pathogen Candida and the bacterial pathogen Staphylococcus aureus (S. aureus), including methicillin-resistant S. aureus (MRSA). These pathogens are increasingly drug-resistant and can lead to recurrent skin and mucosal infections, as well as life-threatening systemic infections. The Company’s founding scientists from the Los Angeles Biomedical Research Institute (LA BioMed) at Harbor-UCLA Medical Center are recognized leaders in the field of infectious disease and the emerging threat of “superbugs.” Based in North Dakota with additional research activities at LA BioMed, NovaDigm has received funding from Domain Associates and RusnanoMedInvest and collaborates with multiple government agencies.

NovaDigm is conducting a Phase 1b/2a clinical trial to evaluate its lead vaccine candidate, NDV-3, in patients diagnosed with recurrent vulvovaginal candidiasis (RVVC), a fungal infection that affects approximately five million women in the United States. Patients interested in learning more can click here for information on the clinical trial and here for more information on RVVC.